



ADDRESS: Pontbeek 61, B-1731 Zellik, Belgium
 WEBSITE: www.redlabs.com
 E-MAIL: info@redlabs.be
 GENERAL MANAGER: Vincent Herst, Ph.D.
 N° OF EMPLOYEES: 6
 YEAR OF FOUNDATION: 1998
 TEL: +32 2 481 53 10
 FAX: +32 2 481 53 11



R.E.D. Laboratories nv

Business Focus

Diagnosics and therapeutics research and development, and related laboratory testing services.

Company Profile

R.E.D. Laboratories is a Belgian biotechnology company developing clinical diagnostic tests and therapeutics for chronic immune diseases, such as Multiple Sclerosis (MS) and Chronic Fatigue Syndrome (CFS).

The company's scientific platform is based on investigating the interferon system, the key anti-viral defence mechanism of the body.

The company is targeting recently discovered cell abnormalities for new drug development as well as developing clinical assays to diagnose, stage and monitor these diseases.

Science & Technology

R.E.D. Laboratories has an in-house research team that focuses its energy and resources in the analysis of the biochemical, molecular, and cellular pathways that are disrupted in chronic immune disease. The result of this effort is that the company has identified numerous diagnostic markers for other chronic immune diseases such as Multiple Sclerosis (MS) and cancer, and in addition has identified, tested and filed patent applications on new drugs to treat CFS and MS.

The company is currently discussing with a number of clinical laboratory companies throughout the world to transfer its diagnostic tests and technology. In therapeutics, Phase I clinical trials are expected to begin in late 2002 to test new compounds in patients with MS and in those with CFS.

Products in Development

A number of diagnostic kits to diagnose these chronic immune diseases.

Commercial Products

Product Name

RNase L Protein Detection
 RNase L Activity Assay
 Actin Detection
 Hepatitis C virus qualitative
 Cytomegalovirus qualitative
 Epstein-Barr virus qualitative
 Herpes Virus 6 Detection qualitative
 Herpes Virus 7 Detection qualitative
 Herpes Virus 8 Detection qualitative
 Hepatitis C virus quantitative
 Cytomegalovirus quantitative
 Epstein-Barr virus quantitative
 Herpes Virus 6 Detection quantitative
 Herpes Virus 7 Detection quantitative
 Herpes Virus 8 Detection quantitative
 Mycoplasma DNA Detection
 Chlamydia DNA Detection qualitative
 Chlamydia DNA Detection qualitative
 Natural Killer Cell Assay
 Nitric Oxide Cellular level quantitative
 Elastase
 PKR Cleavage

Product Description

Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 Hepatitis C infection
 CMV infection, AIDS, transplantation medicine
 Infectious mononucleosis, Leukemias and Lymphomas
 Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 AIDS, Kaposi's sarcoma
 Hepatitis C infection
 CMV infection, AIDS, transplantation medicine
 Infectious mononucleosis, Leukemias and Lymphomas
 Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 AIDS, Kaposi's sarcoma
 AIDS, Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 MS, Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 MS, Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 Cancer, Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 Chronic Immune and Chronic Inflammatory Diseases (CICIDs)
 Chronic Immune and Chronic Inflammatory Diseases (CICIDs)

Financial Information (2003)

Equity ¹	3,063,964 €
Balance Sheet Total	1,641,509 €
Turnover	822,000 €
R&D Expenses	500,000 €



¹ TOTAL EQUITY EXCLUDING PROFITS OR LOSSES FROM THE PREVIOUS YEAR.